Trius Therapeutics Reports 2012 Second Quarter Financial Results
06 août 2012 16h00 HE
|
Trius Therapeutics, Inc.
SAN DIEGO, Aug. 6, 2012 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics...
Trius Therapeutics Commends Congressional Approval of Incentives to Develop Innovative Antibiotics
27 juin 2012 08h00 HE
|
Trius Therapeutics, Inc.
SAN DIEGO, June 27, 2012 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) today commented on the approval by the United States Congress of the Prescription Drug Users Fee Act (PDUFA V) which...
Trius Therapeutics Added to the NASDAQ Biotechnology Index
14 mai 2012 08h00 HE
|
Trius Therapeutics, Inc.
SAN DIEGO, May 14, 2012 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics...
Trius Therapeutics Reports First Quarter 2012 Financial Results
08 mai 2012 16h00 HE
|
Trius Therapeutics, Inc.
SAN DIEGO, May 8, 2012 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for...
Trius to Present at May Investor Conferences
07 mai 2012 16h00 HE
|
Trius Therapeutics, Inc.
SAN DIEGO, May 7, 2012 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that Jeffrey Stein, Ph.D., President and Chief Executive Officer of Trius Therapeutics, will provide a...
Trius to Present at the BioCentury Future Leaders Conference
16 avr. 2012 08h00 HE
|
Trius Therapeutics, Inc.
SAN DIEGO, April 16, 2012 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that Jeffrey Stein, Ph.D., President and Chief Executive Officer of Trius Therapeutics, will...
Trius' Antibiotic Tedizolid Demonstrates High Efficacy in Patients With Cellulitis
02 avr. 2012 07h00 HE
|
Trius Therapeutics, Inc.
SAN DIEGO, April 2, 2012 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today the results of a subgroup analysis from its first Phase 3 investigational study (TR701-112 Trial) in...
Trius Therapeutics Reports Fourth Quarter and Year End 2011 Financial Results
13 mars 2012 08h00 HE
|
Trius Therapeutics, Inc.
SAN DIEGO, March 13, 2012 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics...
Trius to Present at Citi & RBC Investor Conferences
23 févr. 2012 07h00 HE
|
Trius Therapeutics, Inc.
SAN DIEGO, Feb. 23, 2012 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that Jeffrey Stein, Ph.D., President and Chief Executive Officer of Trius Therapeutics, will provide...
Trius Announces Issuance of Tedizolid Patent in China
16 févr. 2012 07h00 HE
|
Trius Therapeutics, Inc.
SAN DIEGO, Feb. 16, 2012 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today the issuance of Patent # 908206 by the State Intellectual Property Office of the People's Republic...